Zoetis Inc. (NYSE:ZTS) Holdings Increased by Key Client Fiduciary Advisors LLC

Key Client Fiduciary Advisors LLC lifted its stake in Zoetis Inc. (NYSE:ZTS) by 25.2% in the second quarter, HoldingsChannel reports. The fund owned 1,487 shares of the company’s stock after purchasing an additional 299 shares during the quarter. Key Client Fiduciary Advisors LLC’s holdings in Zoetis were worth $258,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in ZTS. Sky Investment Group LLC boosted its stake in Zoetis by 2.3% during the second quarter. Sky Investment Group LLC now owns 21,184 shares of the company’s stock valued at $3,672,000 after buying an additional 470 shares in the last quarter. ORG Partners LLC boosted its position in shares of Zoetis by 1,917.6% during the 2nd quarter. ORG Partners LLC now owns 2,179 shares of the company’s stock valued at $376,000 after purchasing an additional 2,071 shares in the last quarter. Howard Capital Management Group LLC grew its stake in shares of Zoetis by 1.9% in the 2nd quarter. Howard Capital Management Group LLC now owns 103,983 shares of the company’s stock worth $18,027,000 after purchasing an additional 1,924 shares during the last quarter. Great Valley Advisor Group Inc. raised its holdings in shares of Zoetis by 19.9% in the 2nd quarter. Great Valley Advisor Group Inc. now owns 30,436 shares of the company’s stock worth $5,276,000 after purchasing an additional 5,050 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in shares of Zoetis by 0.5% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 245,513 shares of the company’s stock worth $42,562,000 after purchasing an additional 1,165 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Down 2.7 %

Shares of ZTS stock traded down $5.00 on Wednesday, hitting $183.38. The company’s stock had a trading volume of 2,122,145 shares, compared to its average volume of 2,772,392. The stock has a market capitalization of $83.68 billion, a price-to-earnings ratio of 35.33, a P/E/G ratio of 2.84 and a beta of 0.86. The firm’s fifty day moving average price is $177.49 and its 200-day moving average price is $175.32. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.07. The business had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. Zoetis’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.41 EPS. Research analysts anticipate that Zoetis Inc. will post 5.84 EPS for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 4th. Stockholders of record on Thursday, July 18th will be given a $0.432 dividend. The ex-dividend date is Thursday, July 18th. This represents a $1.73 annualized dividend and a dividend yield of 0.94%. Zoetis’s dividend payout ratio is 33.14%.

Analyst Ratings Changes

Several research analysts have issued reports on ZTS shares. HSBC decreased their price target on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a research report on Wednesday, May 8th. Piper Sandler lifted their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday. Stifel Nicolaus upped their target price on Zoetis from $180.00 to $200.00 and gave the company a “buy” rating in a report on Monday, August 5th. Argus raised Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Barclays reduced their price objective on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research note on Tuesday, April 23rd. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $217.11.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.